MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany.
Loehlein & Wolf Vet Research, Maistrasse 69, 80337, Munich, Germany.
Parasit Vectors. 2018 Nov 19;11(1):598. doi: 10.1186/s13071-018-3175-z.
A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12-week study in client-owned cats in Germany and Spain.
Eligible households containing at least one cat with at least two fleas and/or two ticks were allocated randomly in a 2:1 ratio to a single treatment with fluralaner plus moxidectin on Day 0, or three 4-weekly treatments with fipronil (Frontline®). Veterinary staff, masked to treatment, completed tick and flea counts on each cat at 14 ± 2 (2 weeks), 28 ± 2 (4 weeks), 56 ± 2 (8 weeks) and 84 ± 2 days (12 weeks) after the initial treatment.
In total, 707 cats (257 with ticks) from 332 households (236 with fleas) were included. Ixodes ricinus (78%) and Rhipicephalus sanguineus complex (18%) ticks were the most commonly identified. Tick and flea counts were lower in the fluralaner plus moxidectin group than in the fipronil group throughout the study and the efficacy of fluralaner plus moxidectin exceeded 97 and 98%, respectively. At 12 weeks, 94.1 and 93.3% of cats from the fluralaner plus moxidectin and 92.2 and 60.3% of cats from the fipronil group were free of ticks and fleas, respectively. Fluralaner plus moxidectin was non-inferior to fipronil (P < 0.0001) at all assessments and superior to fipronil at 2 and 8 weeks for the proportion of cats free of ticks (P < 0.0001). Fluralaner plus moxidectin was superior to fipronil for the proportion of both households and cats free of fleas (P < 0.0001). Both products were safe and well tolerated.
A single application of fluralaner plus moxidectin spot-on was well tolerated by cats and highly effective for 12 weeks against ticks and fleas. Fluralaner plus moxidectin was non-inferior to fipronil for the proportion of ectoparasite-free and consistently superior to fipronil in controlling fleas.
一种含有氟雷拉纳(280mg/ml)和莫昔克丁(14mg/ml)的滴剂配方(Bravecto® Plus)已经被开发出来,用于为猫提供广谱寄生虫保护。在德国和西班牙的一项随机、对照、为期 12 周的研究中,评估了这种产品对蜱虫和跳蚤的有效性和安全性。
符合条件的家庭,每个家庭至少有一只猫,至少有两只跳蚤和/或两只蜱虫,按 2:1 的比例随机分配到一次用氟雷拉纳加莫昔克丁治疗(第 0 天),或三次每四周用非泼罗尼(Frontline®)治疗。兽医工作人员在治疗后 14±2(2 周)、28±2(4 周)、56±2(8 周)和 84±2 天(12 周)对每只猫进行蜱虫和跳蚤计数,对治疗情况不知情。
共有 707 只猫(257 只有蜱虫)来自 332 个家庭(236 只有跳蚤)被纳入研究。蓖子硬蜱(78%)和血红扇头蜱复合体(18%)是最常见的蜱虫。在整个研究过程中,氟雷拉纳加莫昔克丁组的蜱虫和跳蚤计数均低于非泼罗尼组,氟雷拉纳加莫昔克丁的疗效分别超过 97%和 98%。在 12 周时,氟雷拉纳加莫昔克丁组的 94.1%和 93.3%的猫没有蜱虫,非泼罗尼组的 60.3%的猫没有跳蚤。氟雷拉纳加莫昔克丁在所有评估中均不劣于非泼罗尼(P<0.0001),在 2 周和 8 周时,氟雷拉纳加莫昔克丁组的无蜱猫比例均优于非泼罗尼(P<0.0001)。氟雷拉纳加莫昔克丁在无跳蚤的家庭和猫的比例方面均优于非泼罗尼(P<0.0001)。两种产品均安全且耐受性良好。
氟雷拉纳加莫昔克丁滴剂单次应用耐受性良好,对猫的蜱虫和跳蚤有效,持续 12 周。氟雷拉纳加莫昔克丁在无寄生虫的比例上不劣于非泼罗尼,在控制跳蚤方面始终优于非泼罗尼。